![Mark Truesdale](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Mark Truesdale currently works at Solentim Ltd., as Chief Executive Officer & Director.
Postes actifs de Mark Truesdale
Sociétés | Poste | Début |
---|---|---|
Solentim Ltd.
![]() Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Solentim Ltd.
![]() Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Health Technology |